Saturday 17 October 2026
Export SYRA’s income statement to Excel — free account
Syra Health Corp.
SYRA Healthcare Medical Care Facilities
Syra Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.2 million, down 9.47% from fiscal 2024. In the quarter to June 2026, revenue grew 23.0%, EPS grew 477.4% and free cash flow fell 892.7%, each against the same quarter a year earlier.
0.84
0.00
0.00%
Follow SYRA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
64.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.04 | 0.34 | 0.15 | 0.14 | |
P/FCF ratio |
81.00 | 3.50 | 0.00 | 0.00 | |
P/Operating CF |
(11.73) | 1.93 | (3.69) | (4.40) | |
P/B ratio |
3.20 | 1.11 | 0.51 | 0.49 | |
Price to Tangible BV |
3.20 | 1.11 | 0.51 | 0.49 | |
EV/Sales |
1.00 | 0.19 | 0.17 | 0.11 | |
EV/EBITDA |
95.88 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
73.51 | 1.93 | (2.70) | (2.29) | |
EV/FCF |
77.46 | 1.95 | (2.66) | (2.22) | |
Quick Ratio |
3.00 | 2.40 | 3.75 | 2.75 | |
Current Ratio |
3.13 | 2.48 | 4.06 | 3.05 | |
Net Debt/EBITDA |
(8.42) | (15.22) | 12.10 | 8.71 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
2.22 | 1.99 | 2.24 | 1.95 | |
Operating CF/Net income |
(2.87) | 5.65 | 2.15 | 1.08 | |
Capex/Depreciation |
0.00 | 0.00 | (0.04) | 0.00 | |
Interest Coverage |
114.36 | 76.40 | (31.56) | (122.21) | |
Research and Development Expense of Revenue |
1.98% | 0.30% | 0.01% | 0.05% | |
Selling, General and Administrative Expense of Revenue |
26.25% | 25.74% | 32.72% | 34.88% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.88% | 1.02% | 1.35% | 1.25% | |
Graham Net Nets |
0.30 | 0.89 | 1.93 | 2.01 | |
Graham Number |
0.21 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.56% | (6.95%) | (83.67%) | (128.11%) | |
Free Cash Flow Yield |
1.23% | 28.57% | (42.49%) | (35.77%) | |
Revenue per Share |
0.18 | 0.19 | 0.15 | 0.14 | |
Operating CF per Share |
(0.05) | 0.11 | (0.02) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | 0.11 | (0.02) | (0.02) | |
Cash per Share |
0.16 | 0.24 | 0.14 | 0.17 | |
Shareholders Equity per Share |
0.20 | 0.20 | 0.18 | 0.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.20 | 0.20 | 0.18 | 0.19 | |
Free Cash Flow |
(0.72) | 1.36 | (0.29) | (0.24) | |
Working Capital |
2.55 | 2.35 | 2.06 | 2.16 | |
Capital Expenditures |
— | — | 0.00 | — | |
Net Current Asset Value |
2.55 | 2.35 | 2.06 | 2.16 | |
EV/EBIT |
107.95 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
112.88 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.18 | 0.91 | 0.80 | 0.91 | |
Average Payables |
0.38 | 0.35 | 0.17 | 0.27 | |
Average Assets |
3.65 | 3.83 | 3.23 | 3.84 | |
Average Common Equity |
2.52 | 2.41 | 2.49 | 2.77 |
Columns are period end dates